Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Chongqing Tan"'
Autor:
Andong Li, Meiyu Wu, Ouyang Xie, Heng Xiang, Kehui Meng, Chongqing Tan, Long Wang, Xiaomin Wan
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Background and objectiveThe EV-302 trial found that the combination of enfortumab vedotin (EV) with pembrolizumab significantly improved survival for patients with metastatic urothelial carcinoma (mUC). However, given the high cost of the drugs, ther
Externí odkaz:
https://doaj.org/article/b4ce46e9beac4f228c31b672efce7fa8
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveTo determine the cost-effectiveness of imported immune checkpoint inhibitors (ICIs) such as atezolizumab and durvalumab, and domestic ICIs like serplulimab and adebrelimab, in combination with chemotherapy for extensive-stage small cell lung
Externí odkaz:
https://doaj.org/article/27b729f3859d4633a2b39201519ce840
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background China has one of the highest numbers of liver disease cases in the world, including 6.4 million cirrhosis associated with alcohol-related liver disease (ALD) cases. However, there is still a lack of urgent awareness about the grow
Externí odkaz:
https://doaj.org/article/b41f51cd651d4642be696ed3f090a0db
Publikováno v:
Journal of Infection and Public Health, Vol 16, Iss 6, Pp 893-900 (2023)
Background: The sustainability and generalizability of China’s dynamic zero-COVID strategy on eliminating SARS-CoV-2 transmission has casted doubt globally, mainly because it has exacted high social and economic cost. This study aimed to estimate t
Externí odkaz:
https://doaj.org/article/063b2966715a4cab966df2b7e658c3f8
Autor:
Li Zeng, Huihui Chen, Heng Xiang, Mengru Zeng, Mi Zhou, Chongqing Tan, Hong Liu, Guochun Chen
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2024)
Background: Rituximab (RTX) is a monoclonal antibody that selectively targets CD20 and is frequently used in the treatment of membranous nephropathy (MN). Analysis of the therapeutic efficacy and safety of RTX in treating MN in practice and a compara
Externí odkaz:
https://doaj.org/article/409b43efc99742db8bce931b04518b12
Autor:
Huihui Chen, Zhiwen Liu, Jie Zha, Li Zeng, Runyan Tang, Chengyuan Tang, Juan Cai, Chongqing Tan, Hong Liu, Zheng Dong, Guochun Chen
Publikováno v:
Clinical & Translational Immunology, Vol 12, Iss 8, Pp n/a-n/a (2023)
Abstract Objectives Conventional glucocorticoid (GC) treatment poses significant risks for opportunistic infections due to its suppressive impact on CD4+ T cells. This study aimed to explore the mechanisms by which GCs modulate the functionality of C
Externí odkaz:
https://doaj.org/article/d940a9981d13429f9ddeb0b225444b69
Autor:
Liting Wang, Ye Peng, Shuxia Qin, Xiaomin Wan, Xiaohui Zeng, Sini Li, Qiao Liu, Chongqing Tan
Publikováno v:
PLoS ONE, Vol 18, Iss 4, p e0279786 (2023)
BackgroundOral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective for treating advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-effectiveness of oral multikinase inhibitors and ICI
Externí odkaz:
https://doaj.org/article/75b9d97a820e45b3b412c1d1b195b0da
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China.Materials and methods: A Markov model was developed to estimate the long-term health and economic
Externí odkaz:
https://doaj.org/article/9e140024282e4fb48ac1e68fd1c06cd9
Autor:
Shuxia Qin, Xuehong Wang, Sini Li, Chongqing Tan, Xiaohui Zeng, Meiyu Wu, Ye Peng, Liting Wang, Xiaomin Wan
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
ObjectiveCurrent guidelines recommend the gastric cancer risk score scale (GCRSS) for screening in gastric cancer (GC) high-risk populations in China. This study aimed to estimate the clinical benefits, harms, cost, and cost-effectiveness of the GCRS
Externí odkaz:
https://doaj.org/article/58573308c77e46d49725851d7af9a67c
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: Domestic PD-1inhibitor tislelizumab has emerged as a promising treatment for Chinese patients with driver-negative advanced or metastatic non-small cell lung cancer (NSCLC). The purpose of our study to evaluate whether tislelizumab is cost
Externí odkaz:
https://doaj.org/article/92c2c3374d4a4f66bbf2933c593f4b61